JP7594913B2 - 抗体コンジュゲート - Google Patents

抗体コンジュゲート Download PDF

Info

Publication number
JP7594913B2
JP7594913B2 JP2020557617A JP2020557617A JP7594913B2 JP 7594913 B2 JP7594913 B2 JP 7594913B2 JP 2020557617 A JP2020557617 A JP 2020557617A JP 2020557617 A JP2020557617 A JP 2020557617A JP 7594913 B2 JP7594913 B2 JP 7594913B2
Authority
JP
Japan
Prior art keywords
antibody
tau protein
conjugate
epitope
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020557617A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020105700A1 (ja
Inventor
ヘールト ヤネス
マルチネ ダウエ
雄一 石井
涼 岡田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Publication of JPWO2020105700A1 publication Critical patent/JPWO2020105700A1/ja
Priority to JP2024161331A priority Critical patent/JP2024178283A/ja
Application granted granted Critical
Publication of JP7594913B2 publication Critical patent/JP7594913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
JP2020557617A 2018-11-22 2019-11-21 抗体コンジュゲート Active JP7594913B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024161331A JP2024178283A (ja) 2018-11-22 2024-09-18 抗体コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018219558 2018-11-22
JP2018219558 2018-11-22
PCT/JP2019/045589 WO2020105700A1 (ja) 2018-11-22 2019-11-21 抗体コンジュゲート

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024161331A Division JP2024178283A (ja) 2018-11-22 2024-09-18 抗体コンジュゲート

Publications (2)

Publication Number Publication Date
JPWO2020105700A1 JPWO2020105700A1 (ja) 2021-10-07
JP7594913B2 true JP7594913B2 (ja) 2024-12-05

Family

ID=70773827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557617A Active JP7594913B2 (ja) 2018-11-22 2019-11-21 抗体コンジュゲート
JP2024161331A Pending JP2024178283A (ja) 2018-11-22 2024-09-18 抗体コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024161331A Pending JP2024178283A (ja) 2018-11-22 2024-09-18 抗体コンジュゲート

Country Status (5)

Country Link
US (1) US20220018856A1 (https=)
EP (1) EP3885362A4 (https=)
JP (2) JP7594913B2 (https=)
CN (1) CN113166235A (https=)
WO (1) WO2020105700A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021065306A1 (ja) * 2019-09-30 2021-04-08 ニプロ株式会社 血液試料を検体とするタウタンパク質検出方法
CN113533746B (zh) * 2021-07-22 2022-05-10 深圳市天大生物医疗器械有限公司 一种P-Tau蛋白化学发光检测试剂盒及其制备方法
KR102888596B1 (ko) 2021-09-09 2025-11-20 알즈패스, 인크. 포스포-타우 항체 및 사용 방법
CN115015228A (zh) * 2022-02-22 2022-09-06 上海科华生物工程股份有限公司 一种检测血液中p-tau181蛋白的化学发光试剂盒及其制备方法
WO2026029079A1 (ja) * 2024-07-31 2026-02-05 富士レビオ株式会社 リン酸化タウタンパク質の測定方法およびリン酸化タウタンパク質の測定キット

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010189413A (ja) 2002-12-31 2010-09-02 Immunomedics Inc 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法
US20130095492A1 (en) 2010-03-05 2013-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
JP2014523742A (ja) 2011-07-14 2014-09-18 カソリック ウニヴェルシテイト ルーヴェン リン酸化タウ凝集体に対する抗体
JP2018512863A (ja) 2015-04-17 2018-05-24 アイジーエム バイオサイエンシズ エー／エス 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318420T2 (de) 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
DK0737208T3 (da) 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
DE60123752T2 (de) * 2000-01-24 2007-08-23 Innogenetics N.V. Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
US20160356794A1 (en) * 2014-02-10 2016-12-08 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010189413A (ja) 2002-12-31 2010-09-02 Immunomedics Inc 非コンジュゲートおよびコンジュゲート抗体、抗体の組合せおよび融合タンパク質を用いるｂ細胞悪性腫瘍および自己免疫疾患の免疫療法
US20130095492A1 (en) 2010-03-05 2013-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
JP2014523742A (ja) 2011-07-14 2014-09-18 カソリック ウニヴェルシテイト ルーヴェン リン酸化タウ凝集体に対する抗体
JP2018512863A (ja) 2015-04-17 2018-05-24 アイジーエム バイオサイエンシズ エー／エス 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法

Also Published As

Publication number Publication date
JP2024178283A (ja) 2024-12-24
JPWO2020105700A1 (ja) 2021-10-07
EP3885362A1 (en) 2021-09-29
EP3885362A4 (en) 2022-08-17
US20220018856A1 (en) 2022-01-20
CN113166235A (zh) 2021-07-23
WO2020105700A1 (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
JP7594913B2 (ja) 抗体コンジュゲート
EP4130741B1 (en) Method for immunoassay of amyloid beta in blood, and kit for same
US5445936A (en) Method for non-competitive binding assays
US11169148B2 (en) Method for detecting test substance and reagent kit for detecting test substance
KR20210049107A (ko) 바이오마커 검출 방법
JP6713478B2 (ja) Ｐｉｖｋａ−ｉｉの測定方法、及びｐｉｖｋａ−ｉｉ免疫測定試薬又はキットの製造方法
US11802867B2 (en) Cardiac troponin assay method and assay reagent
WO2012161288A1 (en) Immunoassay methods and reagents for decreasing nonspecific binding
JP2023017986A (ja) 自己抗体の直接イムノアッセイ測定法
JP7209498B2 (ja) Ｂ型肝炎ウイルスコア抗体の免疫測定方法
CN117741144A (zh) 对细胞外囊泡中所含的碱性磷酸酶的活性进行测定的方法、校准物及结合体
JPH0727764A (ja) Ｆｃ部位をブロックした免疫学的測定用抗体、該抗体を含む免疫学的測定用試薬、該免疫学的測定用試薬を使用する免疫学的測定法及びＦｃ部位をブロックするブロック試薬
JP7590631B1 (ja) 肺サーファクタントプロテインｄの測定方法、測定キット、モノクローナル抗体及び細胞
JP2024058961A (ja) 肝細胞がんの検出を補助する方法
WO2026004944A1 (ja) 抗ヒトアミロイドβ４２抗体およびポリエチレングリコールの双方を保持する固相
WO2026071006A1 (ja) アミロイドβ前駆体タンパク質由来の被検物質を検出する方法、キレート剤の影響を低減する方法、緩衝液試薬及び試薬キット
CN118359697A (zh) β淀粉样蛋白40及β淀粉样蛋白42特异识别多肽及其应用
JPH05273210A (ja) 免疫測定法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241125

R150 Certificate of patent or registration of utility model

Ref document number: 7594913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150